‘Cancer in all forms is our enemy’ ‘Cancer in all forms is our enemy’ Robert H. Vonderheide, the Abramson Cancer Center director, talks innovation, discoveries, FDA approvals, and how to deliver top-of-the-line cancer care.
Immune cells involved in triple-negative breast cancer could offer future therapeutic target Immune cells involved in triple-negative breast cancer could offer future therapeutic target New research led by Rumela Chakrabarti reveals how immune cells called myeloid-derived immunosuppressor cells contribute to the progression of triple-negative breast cancer, a particularly aggressive cancer. Pairing chemotherapy with a drug that blocks these cells may one day help stem its growth.
Cutting-edge science moves to the clinic to help ‘our furry friends’ fight cancer Cutting-edge science moves to the clinic to help ‘our furry friends’ fight cancer A year after its launch, the Penn Vet Cancer Center is solidifying the translational science pipeline, connecting basic scientists to the clinic and vice versa, to transform veterinary cancer care.
How scientists are treating breast cancer using the immune system Penn In the News Time How scientists are treating breast cancer using the immune system The Abramson Cancer Center’s Robert Vonderheide described challenges in treating breast cancer. Most cases, he said, “fit into a category we call ‘cold’ immunological tumors, meaning the tumor has the ability to either exclude the immune system or hide from it altogether. That kind of cancer isn’t easily treated with current immunotherapies.” Discovering a single cell that leads to relapse Discovering a single cell that leads to relapse Research from the Abramson Cancer Center identified a single leukemic cell, engineered for CAR T therapy, that caused a deadly recurrence of pediatric B-cell acute lymphoblastic leukemia. DNA vaccine leads to immune responses in HPV-related head and neck cancer DNA vaccine leads to immune responses in HPV-related head and neck cancer Researchers from the Abramson Cancer Center find immunotherapy approach can help T cells infiltrate tumors. With CRISPR, scientists engineered nearly 4,000 mutations of a breast-cancer gene Penn In the News The Atlantic With CRISPR, scientists engineered nearly 4,000 mutations of a breast-cancer gene Susan Domchek of the Perelman School of Medicine commented on new research into the BRCA1 gene, describing the work as a “tour de force.” With CRISPR, scientists engineered nearly 4,000 mutations of a breast-cancer gene Penn In the News The Atlantic With CRISPR, scientists engineered nearly 4,000 mutations of a breast-cancer gene Susan Domchek of the Perelman School of Medicine commented on new research into the BRCA1 gene, describing the work as a “tour de force.” Life-saving 'urine-stick' test for early ovarian cancer could boost survival rates to 90 percent Penn In the News Daily Mail (U.K.) Life-saving 'urine-stick' test for early ovarian cancer could boost survival rates to 90 percent The Perelman School of Medicine’s Ronny Drapkin attributed delays in ovarian-cancer diagnoses to both misinterpreted symptoms and the organ’s location within the pelvis. “One of the things I tell women is that nobody knows your body as well as you do. If you feel something isn’t right, something’s probably not right,” Drapkin said. For new cancer treatments, less is more Penn In the News The Washington Post For new cancer treatments, less is more Justin Bekelman, a radiation oncologist at the Perelman School of Medicine, discussed a new approach to cancer treatment that explores more nuanced, less severe steps that favor de-escalating toxic and costly approaches for less aggressive, more prolonged and monitored treatments. Load More
Discovering a single cell that leads to relapse Discovering a single cell that leads to relapse Research from the Abramson Cancer Center identified a single leukemic cell, engineered for CAR T therapy, that caused a deadly recurrence of pediatric B-cell acute lymphoblastic leukemia.
DNA vaccine leads to immune responses in HPV-related head and neck cancer DNA vaccine leads to immune responses in HPV-related head and neck cancer Researchers from the Abramson Cancer Center find immunotherapy approach can help T cells infiltrate tumors.
With CRISPR, scientists engineered nearly 4,000 mutations of a breast-cancer gene Penn In the News The Atlantic With CRISPR, scientists engineered nearly 4,000 mutations of a breast-cancer gene Susan Domchek of the Perelman School of Medicine commented on new research into the BRCA1 gene, describing the work as a “tour de force.” With CRISPR, scientists engineered nearly 4,000 mutations of a breast-cancer gene Penn In the News The Atlantic With CRISPR, scientists engineered nearly 4,000 mutations of a breast-cancer gene Susan Domchek of the Perelman School of Medicine commented on new research into the BRCA1 gene, describing the work as a “tour de force.” Life-saving 'urine-stick' test for early ovarian cancer could boost survival rates to 90 percent Penn In the News Daily Mail (U.K.) Life-saving 'urine-stick' test for early ovarian cancer could boost survival rates to 90 percent The Perelman School of Medicine’s Ronny Drapkin attributed delays in ovarian-cancer diagnoses to both misinterpreted symptoms and the organ’s location within the pelvis. “One of the things I tell women is that nobody knows your body as well as you do. If you feel something isn’t right, something’s probably not right,” Drapkin said. For new cancer treatments, less is more Penn In the News The Washington Post For new cancer treatments, less is more Justin Bekelman, a radiation oncologist at the Perelman School of Medicine, discussed a new approach to cancer treatment that explores more nuanced, less severe steps that favor de-escalating toxic and costly approaches for less aggressive, more prolonged and monitored treatments. Load More
With CRISPR, scientists engineered nearly 4,000 mutations of a breast-cancer gene Penn In the News The Atlantic With CRISPR, scientists engineered nearly 4,000 mutations of a breast-cancer gene Susan Domchek of the Perelman School of Medicine commented on new research into the BRCA1 gene, describing the work as a “tour de force.” Life-saving 'urine-stick' test for early ovarian cancer could boost survival rates to 90 percent Penn In the News Daily Mail (U.K.) Life-saving 'urine-stick' test for early ovarian cancer could boost survival rates to 90 percent The Perelman School of Medicine’s Ronny Drapkin attributed delays in ovarian-cancer diagnoses to both misinterpreted symptoms and the organ’s location within the pelvis. “One of the things I tell women is that nobody knows your body as well as you do. If you feel something isn’t right, something’s probably not right,” Drapkin said. For new cancer treatments, less is more Penn In the News The Washington Post For new cancer treatments, less is more Justin Bekelman, a radiation oncologist at the Perelman School of Medicine, discussed a new approach to cancer treatment that explores more nuanced, less severe steps that favor de-escalating toxic and costly approaches for less aggressive, more prolonged and monitored treatments. Load More
Life-saving 'urine-stick' test for early ovarian cancer could boost survival rates to 90 percent Penn In the News Daily Mail (U.K.) Life-saving 'urine-stick' test for early ovarian cancer could boost survival rates to 90 percent The Perelman School of Medicine’s Ronny Drapkin attributed delays in ovarian-cancer diagnoses to both misinterpreted symptoms and the organ’s location within the pelvis. “One of the things I tell women is that nobody knows your body as well as you do. If you feel something isn’t right, something’s probably not right,” Drapkin said. For new cancer treatments, less is more Penn In the News The Washington Post For new cancer treatments, less is more Justin Bekelman, a radiation oncologist at the Perelman School of Medicine, discussed a new approach to cancer treatment that explores more nuanced, less severe steps that favor de-escalating toxic and costly approaches for less aggressive, more prolonged and monitored treatments. Load More
For new cancer treatments, less is more Penn In the News The Washington Post For new cancer treatments, less is more Justin Bekelman, a radiation oncologist at the Perelman School of Medicine, discussed a new approach to cancer treatment that explores more nuanced, less severe steps that favor de-escalating toxic and costly approaches for less aggressive, more prolonged and monitored treatments.